Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood

Published: 11/01/2019
Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood
Source: WWW.BUSINESSWIRE.COM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2 study of luspatercept in patients with red blood cell (RBC) transfusion-dependent and non-transfusion-dependent beta-tha

Read more
Related news
Comment
FACEBOOK